Saturday 17 October 2026 Export MRVI’s income statement to Excel — free account

Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024. In the quarter to June 2026, revenue grew 8.53%, EPS grew 70.4%, free cash flow grew 127.6% and total debt fell 45.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.79 0.28 −3.96%

Follow MRVI

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: −16.2×
Dividend yield: —
F-score: 2/9
Altman Z: 0.44
Beneish M: −3.30
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.88

Total sells 0.25

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	1	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	1	—	—	—	—

Insider Ownership 24.81%

Capital & Financial Ratios $m

Market Cap 1,840.00

Revenue 208.78

Net Income (136.08)

Free Cash Flow (35.84)

Net Debt 106.61

Current Ratio 4.05

Debt/Equity 0.50

P/E ratio 0.00

Fwd P/E (16.20)

P/S ratio 4.81

P/B ratio 2.83

Past 5Y EPS Growth —

This Y EPS Growth 62.67%

Next Y EPS Growth 7.16%

Next Y revenue growth 14.03%

Next 5Y EPS Growth 37.17%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 75.44%

10-year low 10-year high

P/B against its own 10 years 64.78%

10-year low 10-year high

EV/Sales against its own 10 years 76.79%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	575	322	217	70
Receivables	55	39	25	31
Inventory	51	50	40	41
Other	—	—	—	—
	700	429	296	156

	2023	2024	2025	Q'26
Payables	11	12	3	7
ST’ Debt	5	5	5	1
Other	—	—	—	—
	87	57	45	38

Compound Annual Growth %

	10y	5y	3y
Sales	—	(8.15%)	(40.53%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	19.22%	(25.61%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	66	51	—	—	—
’25	47	47	42	50	186
’24	64	69	69	57	259
’23	79	69	67	74	289
’22	244	243	191	205	883
’21	148	218	205	228	799
’20	51	47	88	98	284

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	9	4	—	—	—
’25	(9)	(10)	(15)	(23)	(58)
’24	(8)	17	13	(15)	7
’23	85	19	14	8	126
’22	162	164	110	99	536
’21	38	166	106	59	369
’20	10	12	51	79	152

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	4	4	—	—	—
’25	(14)	(13)	(19)	(25)	(71)
’24	(14)	8	5	(20)	(22)
’23	77	(6)	(2)	(9)	61
’22	160	163	104	93	519
’21	36	161	104	53	354
’20	41	9	41	71	161

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.02)	(0.08)	—	—	—
’25	(0.21)	(0.27)	(0.18)	(0.24)	(0.90)
’24	(0.09)	(0.05)	(0.70)	(0.18)	(1.05)
’23	0.00	(0.05)	(0.05)	(0.80)	(0.90)
’22	0.50	0.53	0.34	0.28	1.67
’21	0.24	0.44	0.23	0.42	1.56
’20	0.09	0.01	0.15	0.13	2.36

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	23.62	25.32	12.16	4.52	4.28	1.67	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	32.46	63.55	41.87	16.90	11.56	6.21
People
People	Employees	—	—	—	390	58	470	610	650	570	435
	Revenue/emp, $m	—	—	0.00	0.37	4.90	1.70	1.45	0.44	0.45	0.43
Income, $m
Income, $m	Revenue	—	—	124	143	284	799	883	289	259	186
	Gross margin, %	—	—	50.93	53.30	71.96	82.41	80.87	48.52	41.79	18.30
	EBT	—	—	(16)	(6)	82	531	551	618	(261)	(235)
	EBT margin, %	—	—	(13.32)	(4.09)	28.76	66.41	62.45	213.79	(100.89)	(126.50)
	Net income	—	0	(17)	(5)	79	469	491	(138)	(260)	(231)
	Depreciation	—	—	24	26	28	36	41	52	60	62
Per share, $
Per share, $	Revenue	—	—	0.49	0.56	27.45	6.96	6.71	2.19	1.88	1.29
	Earnings	—	—	(0.07)	(0.02)	7.43	1.59	1.67	(0.90)	(1.05)	(0.90)
	Cash flow	—	—	0.00	0.10	14.70	3.21	4.07	0.96	0.05	(0.40)
	Capex	—	—	(0.01)	(0.07)	0.88	(0.12)	(0.13)	(0.50)	(0.22)	(0.09)
	Free cash flow	—	—	(0.01)	0.03	15.58	3.09	3.94	0.46	(0.16)	(0.49)
	Book value	—	—	0.58	0.57	14.95	4.75	6.88	5.99	4.19	2.58
	Shares, m	—	—	254	254	10	115	132	132	138	144
Valuation, ×
Valuation, ×	P/E	—	—	162.76	162.76	32.87	26.86	8.20	0.00	0.00	0.00
	P/S	—	—	34.19	34.19	3.99	6.02	2.04	3.08	2.90	2.53
	P/B	—	—	52.41	52.41	7.33	8.82	1.99	1.13	1.30	1.26
	EV/Sales	—	—	35.84	35.84	5.24	5.99	1.92	3.01	2.92	3.09
	EV/FCF	—	—	81.35	81.35	9.23	13.52	3.27	14.34	(34.07)	(8.12)
Cash, $m
Cash, $m	Operating cash flow	—	—	0	24	152	369	536	126	7	(58)
	Capex	—	—	(4)	(17)	9	(14)	(17)	(66)	(30)	(13)
	Free cash flow	—	—	(4)	7	161	354	519	61	(22)	(71)
Balance, $m
Balance, $m	Working capital	—	—	18	31	201	646	738	612	372	251
	Total debt	—	—	340	390	591	531	527	556	327	322
	Net debt	—	—	318	366	355	(21)	(105)	(19)	5	105
	Shareholders’ equity	—	—	148	145	155	545	905	790	577	373
Returns, %
Returns, %	ROA	—	—	(1.66)	(0.80)	8.32	11.42	10.48	(6.31)	(11.61)	(14.70)
	ROIC	—	—	2.20	2.94	14.71	66.07	44.83	(2.57)	(25.31)	(28.16)
	ROE	—	—	(3.14)	(3.05)	51.37	52.00	30.36	(14.04)	(21.19)	(27.53)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MLYS Mineralys Therapeutics, Inc.	$1.9B	— (loss-making)	—	—	n/m	−7.91% (below 0%: shrinking)	—	0.00%	Compare
SRPT Sarepta Therapeutics, Inc.	$1.9B	— (loss-making)	4.4×	−34.34% (below 0%: shrinking)	n/m	−14.48% (below 0%: shrinking)	62.77%	3.31%	Compare
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)
ZYME Zymeworks Inc.	$1.8B	— (loss-making)	16.2×	−90.58% (below 0%: shrinking)	n/m	−385.53% (below 0%: shrinking)	(497.71%)	(918.95%)	Compare
PVLA Palvella Therapeutics, Inc.	$1.8B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)	Compare
URGN Urogen Pharma	$1.8B	— (loss-making)	— (loss-making)	+199.22% (above 0%: growing)	n/m	+17.26% (above 0%: growing)	90.93%	0.15%	Compare
XNCR Xencor, Inc.	$1.8B	— (loss-making)	— (loss-making)	+17.46% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	(72.37%)	Compare
VIR Vir Biotechnology, Inc.	$1.8B	— (loss-making)	— (loss-making)	+19,582.54% (above 0%: growing)	n/m	+200.47% (above 0%: growing)	100.00%	30.75%	Compare
Median of peers	$1.8B	—	—	−13.41%	—	−33.69%	90.93%	0.00%

All 614 Biotechnology stocks →

Maravai LifeSciences Holdings, Inc. (MRVI) key facts

Concern: Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
Maravai LifeSciences Holdings, Inc. (MRVI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MRVI traded at $6.79, a market capitalization of $1.8 billion.
Return on equity was −27.5% and debt-to-equity 0.50.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.44 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.